Diagnosing recurrent neuroblastoma requires careful testing to determine if the cancer has returned after treatment. Regular monitoring through scheduled scans and examinations helps doctors detect relapse early, even before symptoms appear, giving families and medical teams critical information needed to plan the next steps in care.

Introduction: Who Should Undergo Diagnostics

Children who have completed treatment for neuroblastoma need ongoing diagnostic monitoring to watch for any signs that the cancer might return. This is particularly important for those who were treated for high-risk disease, as approximately half of these children will experience a relapse after achieving initial remission. The disease coming back is called relapsed neuroblastoma, while cancer that never responded to the first treatment is termed refractory neuroblastoma.^[1]

After finishing neuroblastoma treatment, your child will have regularly scheduled scans for approximately three years. These routine follow-up appointments are essential because relapse often happens within the first two years after stem cell transplant or completing chemotherapy. The likelihood of relapse decreases with each passing year after successful treatment, making early detection through consistent monitoring crucial.^[2][7]

It is advisable to seek diagnostics whenever new or concerning symptoms appear, even between scheduled appointments. Many relapses are actually discovered during routine imaging scans before any symptoms develop. However, if your child experiences unexplained pain, new areas of swelling, persistent fatigue, or any other worrying signs, contact your medical team immediately. Pain is the most common symptom when neuroblastoma returns, though many children have no symptoms at all when relapse is first detected.^[2][8]

Children with low-risk or intermediate-risk neuroblastoma who achieved remission also need monitoring, though their risk of relapse is much lower, occurring in only 5 to 15 percent of cases. These children may have different surveillance schedules based on their specific risk category and treatment history.^[2][14]

Diagnostic Methods for Detecting Relapsed Neuroblastoma

When relapse is suspected, whether because of symptoms or concerning findings on routine scans, your child will undergo a comprehensive series of tests to determine the extent of disease recurrence. These diagnostic procedures help doctors understand where the neuroblastoma has returned and how widespread it may be, which is essential information for planning treatment.^[1][8]

Imaging Tests

A computerized tomography scan, commonly called a CT or CAT scan, uses special X-ray equipment to create detailed cross-sectional images of the body. This test can reveal tumors in various locations and show how large they are. CT scans are painless, though your child will need to lie still inside the scanning machine for a period of time.^[1][8]

Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves instead of X-rays to create detailed pictures of organs and tissues inside the body. MRI scans are particularly useful for viewing soft tissues and can provide different information than CT scans. Like CT scans, MRI requires your child to remain still during the procedure, which may take longer than other imaging tests.^[1][8]

A bone scan helps doctors determine if neuroblastoma has spread to the bones. During this test, a small amount of radioactive material is injected into a vein, and special cameras detect areas where the material collects, which may indicate cancer cells in the bones.^[1][8]

The metaiodobenzylguanidine scan, commonly called an MIBG scan, is particularly important for neuroblastoma diagnosis. This specialized test uses a small amount of radioactive iodine linked to a very specific neuroblastoma chemical. Because neuroblastoma cells take up this substance, the scan can detect even small amounts of cancer throughout the body. An MIBG scan shows where neuroblastoma is located, helping distinguish it from other conditions.^[2][15][21]

Laboratory Tests

Urine tests measure levels of certain substances that neuroblastoma cells produce. When these cancer cells break down chemicals called catecholamines, they release substances with complicated names: vanillylmandelic acid (VMA) and homovanillic acid (HVA). Higher than normal amounts of VMA or HVA in the urine can signal that neuroblastoma is present.^[3]

Blood tests provide important information about your child’s overall health and can detect substances that may indicate neuroblastoma activity. These tests examine various components in the blood to help doctors understand what is happening inside your child’s body.^[1][8]

Bone Marrow Examination

A bone marrow biopsy and aspiration involve removing small samples of bone marrow, usually from the hip bone, to examine under a microscope. Bone marrow is the spongy tissue inside bones where blood cells are made, and neuroblastoma often spreads to this area. During aspiration, liquid bone marrow is withdrawn through a needle. A biopsy involves removing a small piece of solid bone marrow tissue. These procedures are typically done under sedation or anesthesia so your child does not feel pain.^[1][8]

Tumor Biopsy

In some cases, doctors may order a tumor biopsy, where surgeons or interventional radiologists remove either a piece of the tumor or the entire tumor, depending on its location and size. Pediatric pathologists then analyze this tissue, and important additional tests are performed to determine the tumor biology. These tests include genetic studies that look for specific changes in the cancer cells, which can influence treatment decisions.^[1][8]

The symptoms of relapsed neuroblastoma vary greatly depending on the size and location of the tumor and whether the cancer has spread to other parts of the body. While neuroblastoma usually begins in the abdomen, especially in the tissues of the adrenal glands (small organs that sit on top of the kidneys), it may also appear in nerve tissues in the neck, chest, or pelvis. These tumors often spread to lymph nodes, liver, bones, and bone marrow.^[1][8]

Specific symptoms that may prompt diagnostic testing include an abdominal mass, enlarged lymph nodes in the neck, swelling and bruising around the eyes, unexplained fevers, bone pain, limping, weakness or paralysis, weight loss, poor appetite, and uncontrolled eye or leg movements. Each of these signs deserves medical attention, as they may indicate that neuroblastoma has returned.^[1][8]

Diagnostics for Clinical Trial Qualification

When considering clinical trials for relapsed or refractory neuroblastoma, children undergo diagnostic testing not only to confirm the disease status but also to determine if they meet specific eligibility criteria. Clinical trials often have strict requirements about the type, location, and extent of disease, as well as the child’s previous treatments and overall health condition.^[4]

The same diagnostic tests used to detect relapse—including imaging scans, bone marrow examination, urine tests, and blood tests—provide essential information that researchers need to determine trial eligibility. However, clinical trials may require additional or more frequent testing to establish baseline measurements before experimental treatment begins. These baseline results become the reference point for measuring how well the trial treatment is working.^[2][8]

Genetic testing of tumor tissue has become increasingly important for clinical trial qualification. Many newer trials focus on targeted therapies, which are treatments designed to attack cancer cells with specific genetic abnormalities. For example, some trials test drugs called ALK inhibitors, which specifically target neuroblastoma cells that have an abnormal ALK gene. To qualify for these trials, diagnostic testing must confirm that the tumor carries this particular genetic change.^[9][19]

Researchers conducting clinical trials for relapsed neuroblastoma are investigating various treatment approaches. Some studies compare different types of intensive chemotherapy combinations. Others examine targeted cancer drugs, which work by targeting specific differences in cancer cells that help them grow and survive. Still others explore immunotherapy treatments, which help the immune system recognize and attack cancer cells more effectively.^[5][10][22]

One area of research involves comparing high-dose chemotherapy with molecular radiotherapy. Molecular radiotherapy uses substances similar to those used in MIBG diagnostic scans but delivers higher doses of radioactive iodine that cancer cells absorb, causing them to die. Determining whether a child’s tumor takes up MIBG during diagnostic scanning is crucial for knowing if this type of treatment might work.^[5][10][22]

Some clinical trials investigate combinations of chemotherapy drugs with targeted cancer drugs like bevacizumab, a type of monoclonal antibody that targets the tumor’s blood supply. By cutting off blood flow to the tumor, researchers hope to starve cancer cells. Diagnostic imaging helps determine if a child’s tumor has the characteristics that would make it susceptible to this approach.^[5][10][22]

The treatment approach for children with refractory neuroblastoma is similar to that for children with relapsed disease. Approximately 15 percent of children with high-risk neuroblastoma have tumors that do not respond to initial treatment, making them candidates for the same diagnostic evaluations used for relapsed disease.^[1][8]

Diagnostic testing must consider the child’s treatment history, including what therapies they have already received and any side effects they experienced. This information helps doctors determine which additional diagnostic procedures are safe and necessary. For example, a child who has already received significant radiation may need different imaging approaches to minimize additional radiation exposure.^[5][10][22]

The location where the neuroblastoma has returned significantly impacts both diagnostic testing and treatment planning. When disease recurs in only one area, called localized relapse, the prognosis is generally better than when it recurs in multiple locations such as bones and bone marrow. Comprehensive diagnostic imaging helps determine whether the relapse is localized or widespread, which is crucial information for treatment decisions.^[9][19]

Understanding that tumors often emerge with no known cause can help families cope with the diagnosis of relapsed disease. Many relapses result from complex interactions between genetic and environmental factors that are not fully understood. The diagnostic process focuses on identifying where the cancer is now and what can be done about it, rather than assigning blame or searching for preventable causes.^[1][8]